Vivos Therapeutics (VVOS) Provides Update on Revenue Recognition Review
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- S&P 500, Nasdaq fall as investors juggle earnings, Mideast risks and tariffs
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil retreats from above $100, still set for weekly rise on Middle East escalation
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Meta’s new seller app hits eBay where it hurts most
Vivos Therapeutics Provides Update on Revenue Recognition Review
November 22, 2022 7:30 AM ESTDetailed Analysis Finds Minimal Impact on Prior Financial Results;No Previously Reported Revenue to be Lost
Previously Reported First Quarter 2022 Revenue Expected to Increase Approximately $200,000; No Need to Restate Prior Year Financial Statements
Restated First Quarter 2022 Results to be Filed Shortly;Second and Third Quarter 2022 Financial Results Expected By Year End
HIGHLANDS RANCH, Colo., Nov. 22, 2022 (GLOBE NEWSWIRE) --... More
